Top

Published in:

01-01-2017 | Review Article

Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments

Authors: P. Zarzosa, N. Navarro, I. Giralt, C. Molist, A. Almazán-Moga, I. Vidal, A. Soriano, M. F. Segura, R. Hladun, A. Villanueva, S. Gallego, J. Roma

Published in: Clinical and Translational Oncology | Issue 1/2017

Abstract

The use of preclinical models is essential in translational cancer research and especially important in pediatric cancer given the low incidence of each particular type of cancer. Cell line cultures have led to significant advances in cancer biology. However, cell lines have adapted to growth in artificial culture conditions, thereby undergoing genetic and phenotypic changes which may hinder the translational application. Tumor grafts developed in mice from patient tumor tissues, generally known as patient-derived xenografts (PDXs), are interesting alternative approaches to reproducing the biology of the original tumor. This review is focused on highlighting the interest of PDX models in pediatric cancer research and supporting strategies of personalized medicine. This review provides: (1) a description of the background of PDX in cancer, (2) the particular case of PDX in pediatric cancer, (3) how PDX can improve personalized medicine strategies, (4) new methods to increase engraftment, and, finally, (5) concluding remarks.

Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions. Adv Pharmacol Chemother. 1984;20:1–20.CrossRefPubMed

Boyd MR. The NCI in vitro antitumor drug discovery screen: concept, implementation, and operation, 1985–1995. In: Teicher BA, editor. Anticancer drug development guide. Totowa: Humana; 1997. p. 23–42.CrossRef

Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73.CrossRefPubMedPubMedCentral

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumor xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.CrossRefPubMedPubMedCentral

Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4(11):1670–80.CrossRefPubMedPubMedCentral

Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.CrossRefPubMedPubMedCentral

Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, et al. Establishment of a patient-derived orthotopic osteosarcoma mouse model. J Transl Med. 2015;13:136.CrossRefPubMedPubMedCentral

Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med. 2012;10:125.CrossRefPubMedPubMedCentral

Shorthouse AJ, Peckham MJ, Smyth JF, Steel GG. The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl. 1980;4:142–5.PubMedPubMedCentral

10.

Fujita M, Hayata S, Taguchi T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. J Surg Oncol. 1980;15(3):211–9.CrossRefPubMed

11.

Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42:535–9.PubMed

12.

Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res. 1985;97:77–86.CrossRefPubMed

13.

Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012;18(19):5399–411.CrossRefPubMed

14.

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.CrossRefPubMedPubMedCentral

15.

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–31.CrossRefPubMedPubMedCentral

16.

Zayed AA, Mandrekar SJ, Haluska P. Molecular and clinical implementations of ovarian cancer mouse avatar models. Chin Clin Oncol. 2015;4(3):30.PubMedPubMedCentral

17.

Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, et al. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res. 2014;20(3):658–67.CrossRefPubMed

18.

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, et al. Combined inhibition of Ddr1 and notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med. 2016;22(3):270–7.CrossRefPubMed

19.

Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170:793–804.CrossRefPubMedPubMedCentral

20.

Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217–21.CrossRefPubMed

21.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol. 2009;3(5–6):469–82.CrossRefPubMed

22.

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015;136(5):E252–61.CrossRefPubMed

23.

Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al. The national cancer data base report on patterns of childhood cancers in the United States. Cancer. 1997;80(12):2321–32.CrossRefPubMed

24.

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8(12):3646–57.PubMed

25.

Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–40.CrossRefPubMed

26.

Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds P, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;54(5):707–15.PubMedPubMedCentral

27.

Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Dev Biol. 2016;411:287–93.CrossRefPubMed

28.

The EurOPDX consortium. 2016. http://europdx.eu/. Accessed 29 July 2016.

29.

Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, et al. Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology. 2016;64(4):1121–35.CrossRefPubMed

30.

Bissig-Choisat B, Kettlun-Leyton C, Legras XD, Zorman B, Barzi M, Chen LL, et al. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016;65(2):325–33.CrossRefPubMed

31.

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 2016;375(2):384–9.CrossRefPubMed

32.

Rodríguez-Hernández CJ, Mateo-Lozano S, García M, Casalà C, Briansó F, Castrejón N, et al. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget. 2016;7(13):16112–29.PubMedPubMedCentral

33.

Krytska K, Ryles HT, Sano R, Raman P, Infarinato NR, Hansel TD, et al. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin Cancer Res. 2016;22(4):948–60.CrossRefPubMed

34.

Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Preclinical childhood sarcoma models: drug efficacy biomarker identification and validation. Front Oncol. 2015;5:193.CrossRefPubMedPubMedCentral

35.

Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer. 2014;61:1570–7.CrossRefPubMed

36.

Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, et al. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015;4(6):871–86.CrossRefPubMedPubMedCentral

37.

Bult CJ, Krupke DM, Begley DA, Richardson JE, Neuhauser SB, Sundberg JP, et al. Mouse Tumor Biology (MTB): a database of mouse models for human cancer. Nucleic Acids Res. 2015;43(Database issue): D818–D824.

38.

Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315–9.CrossRefPubMedPubMedCentral

39.

Cassidy JW, Caldas C, Bruna A. Maintaining tumour heterogeneity in patient-derived tumour xenografts. Cancer Res. 2015;75(15):2963–8.CrossRefPubMedPubMedCentral

40.

Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner D. Humanized mice for immune system investigation: progress, promise and challenges. Nature Rev Immunol. 2012;12(11):786–98.CrossRef

41.

Singh Z. Applications and toxicity of graphene family nanomaterials and their composites. Nanotechnol Sci Appl. 2016;9:15–28.CrossRefPubMedPubMedCentral

42.

De la Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T, Lopez-Lopez R, et al. M-trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107:1–10.

43.

Dong Z, Imai A, Krishnamurthy S, Zhang Z, Zeitlin BD, Nör JE. Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study. PLoS One. 2013;8(12):e84236.CrossRefPubMedPubMedCentral

44.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–4.CrossRefPubMedPubMedCentral

45.

Green JL, La J, Yum KW, Desai P, Rodewald LW, Zhang X, et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci USA. 2013;110(17):6991–6.CrossRefPubMedPubMedCentral

46.

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514–20.CrossRefPubMedPubMedCentral

Title: Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments
Authors: P. Zarzosa
N. Navarro
I. Giralt
C. Molist
A. Almazán-Moga
I. Vidal
A. Soriano
M. F. Segura
R. Hladun
A. Villanueva
S. Gallego
J. Roma
Publication date: 01-01-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 1/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1557-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer

Bone marrow-derived cells are recruited by the melanoma tumor with endothelial cells contributing to tumor vasculature

Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer